{"classes":[{"categories":[{"measurements":[{"comment":"The median and 95% CI were calculated with the Kaplan Meier process (a process in medical research to measure the proportion of participants surviving for a certain time after receiving treatment) and were non estimable as there was insufficient number of participants with the event of interest (less than 50%) occurred in the study.","groupId":"OG000","lowerLimit":"1.8","upperLimit":"NA","value":"NA"},{"comment":"The 95% CI was calculated with the Kaplan Meier process (a process in medical research to measure the proportion of participants surviving for a certain time after receiving treatment) and was non estimable as there was insufficient number of participants with the event of interest (less than 50%) occurred in the study.","groupId":"OG002","lowerLimit":"1.9","upperLimit":"NA","value":"5.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"Duration of response is defined as the time from the first objective response to the time of documented disease progression or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG000","title":"Cohort 1 Non-NK PTCL"},{"description":"Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG001","title":"Cohort 2 NK PTCL"},{"description":"Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG002","title":"Cohort 3 cHL"}],"paramType":"MEDIAN","populationDescription":"Response evaluable set included all dosed participants who have measurable disease at baseline and had objective response.","reportingStatus":"POSTED","timeFrame":"From Screening (Day -30 to Day-1) until disease progression or survival until death (26 months).","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Months"}